Neisseria Gonorrhoeae Infections Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4144584
- 100 Pages
- December 2020
- Healthcare
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Neisseria Gonorrhoeae Infections Treatment market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Neisseria Gonorrhoeae Infections Treatment market segmented into
Cribrostatin-6
Dalbavancin
Debio-1453
Gepotidacin Mesylate
Others
Based on the end-use, the global Neisseria Gonorrhoeae Infections Treatment market classified into
Clinic
Hospital
Others
Based on geography, the global Neisseria Gonorrhoeae Infections Treatment market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Allergan Plc
BioDiem Ltd
Biolytics Pharma
Debiopharm International SA
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Paratek Pharmaceuticals, Inc.
Recce Pty Ltd
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NEISSERIA GONORRHOEAE INFECTIONS TREATMENT INDUSTRY
2.1 Summary about Neisseria Gonorrhoeae Infections Treatment Industry
2.2 Neisseria Gonorrhoeae Infections Treatment Market Trends
2.2.1 Neisseria Gonorrhoeae Infections Treatment Production & Consumption Trends
2.2.2 Neisseria Gonorrhoeae Infections Treatment Demand Structure Trends
2.3 Neisseria Gonorrhoeae Infections Treatment Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Cribrostatin-6
4.2.2 Dalbavancin
4.2.3 Debio-1453
4.2.4 Gepotidacin Mesylate
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Hospital
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Cribrostatin-6
5.2.2 Dalbavancin
5.2.3 Debio-1453
5.2.4 Gepotidacin Mesylate
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Hospital
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Cribrostatin-6
6.2.2 Dalbavancin
6.2.3 Debio-1453
6.2.4 Gepotidacin Mesylate
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Cribrostatin-6
7.2.2 Dalbavancin
7.2.3 Debio-1453
7.2.4 Gepotidacin Mesylate
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Hospital
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Cribrostatin-6
8.2.2 Dalbavancin
8.2.3 Debio-1453
8.2.4 Gepotidacin Mesylate
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Hospital
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Cribrostatin-6
9.2.2 Dalbavancin
9.2.3 Debio-1453
9.2.4 Gepotidacin Mesylate
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Hospital
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Allergan Plc
10.1.2 BioDiem Ltd
10.1.3 Biolytics Pharma
10.1.4 Debiopharm International SA
10.1.5 F. Hoffmann-La Roche Ltd.
10.1.6 GlaxoSmithKline Plc
10.1.7 Merck & Co., Inc.
10.1.8 Paratek Pharmaceuticals, Inc.
10.1.9 Recce Pty Ltd
10.1.10 Redx Pharma Plc
10.1.11 Sarepta Therapeutics, Inc.
10.1.12 Sumitomo Dainippon Pharma Co., Ltd
10.2 Neisseria Gonorrhoeae Infections Treatment Sales Date of Major Players (2017-2020e)
10.2.1 Allergan Plc
10.2.2 BioDiem Ltd
10.2.3 Biolytics Pharma
10.2.4 Debiopharm International SA
10.2.5 F. Hoffmann-La Roche Ltd.
10.2.6 GlaxoSmithKline Plc
10.2.7 Merck & Co., Inc.
10.2.8 Paratek Pharmaceuticals, Inc.
10.2.9 Recce Pty Ltd
10.2.10 Redx Pharma Plc
10.2.11 Sarepta Therapeutics, Inc.
10.2.12 Sumitomo Dainippon Pharma Co., Ltd
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
Table Neisseria Gonorrhoeae Infections Treatment Product Type Overview
Table Neisseria Gonorrhoeae Infections Treatment Product Type Market Share List
Table Neisseria Gonorrhoeae Infections Treatment Product Type of Major Players
Table Brief Introduction of Allergan Plc
Table Brief Introduction of BioDiem Ltd
Table Brief Introduction of Biolytics Pharma
Table Brief Introduction of Debiopharm International SA
Table Brief Introduction of F. Hoffmann-La Roche Ltd.
Table Brief Introduction of GlaxoSmithKline Plc
Table Brief Introduction of Merck & Co., Inc.
Table Brief Introduction of Paratek Pharmaceuticals, Inc.
Table Brief Introduction of Recce Pty Ltd
Table Brief Introduction of Redx Pharma Plc
Table Brief Introduction of Sarepta Therapeutics, Inc.
Table Brief Introduction of Sumitomo Dainippon Pharma Co., Ltd
Table Products & Services of Allergan Plc
Table Products & Services of BioDiem Ltd
Table Products & Services of Biolytics Pharma
Table Products & Services of Debiopharm International SA
Table Products & Services of F. Hoffmann-La Roche Ltd.
Table Products & Services of GlaxoSmithKline Plc
Table Products & Services of Merck & Co., Inc.
Table Products & Services of Paratek Pharmaceuticals, Inc.
Table Products & Services of Recce Pty Ltd
Table Products & Services of Redx Pharma Plc
Table Products & Services of Sarepta Therapeutics, Inc.
Table Products & Services of Sumitomo Dainippon Pharma Co., Ltd
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Neisseria Gonorrhoeae Infections Treatment Market Forecast (Million USD) by Region 2021f-2026f
Table Global Neisseria Gonorrhoeae Infections Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Neisseria Gonorrhoeae Infections Treatment Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Neisseria Gonorrhoeae Infections Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
